Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 1

Status

Completed 4

Sponsor Class

INDUSTRY 4NIH 1FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 805Carcinoma, Non-Small-Cell Lung 767Breast Neoplasms 731Neoplasm Metastasis 340Colorectal Neoplasms 339Prostatic Neoplasms 324Multiple Myeloma 309Melanoma 305Recurrence 237Ovarian Neoplasms 236Leukemia, Myeloid, Acute 236Lymphoma, Non-Hodgkin 213Lung Neoplasms 211Carcinoma, Renal Cell 200Lymphoma 189Lymphoma, Follicular 163Pancreatic Neoplasms 157Leukemia, Lymphocytic, Chronic, B-Cell 149Carcinoma, Hepatocellular 140Stomach Neoplasms 137Leukemia 133Head and Neck Neoplasms 128Lymphoma, Large B-Cell, Diffuse 126Parkinson Disease 4, Autosomal Dominant Lewy Body 119Squamous Cell Carcinoma of Head and Neck 110Urinary Bladder Neoplasms 109Carcinoma 101Small Cell Lung Carcinoma 99Triple Negative Breast Neoplasms 97Glioblastoma 96

Interventions

Vaccines 3Herpes Zoster Vaccine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Herpes Zoster × Clear all
NCT01798056 2021-05-13

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy

GlaxoSmithKline

Phase 3 Completed
237 enrolled 20 charts

Herpes Zoster

NCT01254630 2019-09-30

V212-011

Merck Sharp & Dohme LLC

Phase 3 Completed
5,305 enrolled 20 charts
Other hematologic neoplasm

Herpes Zoster, Hematologic Neoplasms

NCT01460719 2019-03-11

V212-013

Merck Sharp & Dohme LLC

Phase 1 Completed
80 enrolled 13 charts

Herpes Zoster

NCT01767467 2018-06-06

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

GlaxoSmithKline

Phase 3 Completed
568 enrolled 26 charts

Herpes Zoster

Data powered by HemOnc (CC BY 4.0) Colophon âš¡